Document is current
Any future updates will be listed below
-
Authors
Bilder, Deborah A.
Worsham, Whitney
Sullivan, Scott
Esplin, M. Sean
Burghardt, Paul
Fraser, Alison
Bakian, Amanda V.
-
Funding
Funding for this research was provided by:
University of Utah Neuroscience Initiative
- License Information
-
More Information
Article History
Received: 16 March 2023
Accepted: 1 August 2023
First Online: 12 August 2023
Declarations
:
: Informed consent was obtained at the time of the FASTER study from Utah participants to allow use of their residual serum samples in future research studies such as the current study. Approval for this study was obtained from the Utah Registry of Autism and Developmental Disabilities Oversight Committee, the Utah State Office of Education, and Institutional Review Boards of the University of Utah, Intermountain Healthcare, Utah Department of Health and Human Services, and Resource for Genetic and Epidemiologic Research Review Committee.
: In the interest of full disclosure for consideration of any potential conflicts of interest, Dr Bilder is a member of the Scientific Advisory Board for Taysha Gene Therapies and a consultant for Encoded Therapeutics, BioMarin Pharmaceuticals, and Synlogic Therapeutics. These companies develop biologics that treat rare, single gene disorders and are not developing products to treat autism. The other authors have no potential conflicts of interests to disclose.
